New Delhi, Sep 2 (PTI) Drug firm Granules India on Thursday said it has received licence from Defence Research & Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).

Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.

Also Read | Samsung Galaxy Tab S7 FE Wi-Fi Variant Launched in India at Rs 41,999.

"Granules is working closely with DRDO team to launch the product in India at the earliest," it added.

The drug reduces a patient's average recovery time by two and half days and oxygen demand by up to 40 percent, the filing said.

Also Read | JioPhone Next Prices To Be Announced Next Week, Here's How You Could Buy It at Just Rs 500.

Shares of Granules India closed at Rs 344.20 per scrip on BSE, down 0.22 percent from the previous close.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)